Evidence map›Paper›PMID 25516092›Full record

ArticleJournal of the International AIDS Society2014

Characteristics and comprehensiveness of adult HIV care and treatment programmes in Asia-Pacific, sub-Saharan Africa and the Americas: results of a site assessment conducted by the International epidemiologic Databases to Evaluate AIDS (IeDEA) Collaboration.

Stephany N Duda, Amanda M Farr, Mary Lou Lindegren, Meridith Blevins, C William Wester, Kara Wools-Kaloustian, Didier K Ekouevi, Matthias Egger, Jennifer Hemingway-Foday, David A Cooper and 4 more

Abstract read
In one paragraph

Article in Journal of the International AIDS Society, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Cryptococcal Meningitis and Clinical Outcomes in Persons With Human Immunodeficiency Virus: A Global View.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Clinic-Level Factors Associated With Time to Antiretroviral Initiation and Viral Suppression in a Large, Urban Cohort.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Stephany N DudaDepartment of Biomedical Informatics, Vanderbilt School of Medicine, Nashville, TN, USA; stephany.duda@vanderbilt.edu.
Amanda M FarrDepartment of Life Sciences, Truven Health Analytics, Cambridge, MA, USA; School of Public Health, City University of New York, New York, NY, USA.
Mary Lou LindegrenDepartment of Pediatrics, Vanderbilt School of Medicine, Nashville, TN, USA; Department of Health Policy, Vanderbilt School of Medicine, Nashville, TN, USA.
Meridith BlevinsDepartment of Biostatistics, Vanderbilt School of Medicine, Nashville, TN, USA; Vanderbilt Institute for Global Health (VIGH), Nashville, TN, USA.
C William WesterVanderbilt Institute for Global Health (VIGH), Nashville, TN, USA; Department of Medicine, Division of Infectious Diseases, Vanderbilt School of Medicine, Nashville, TN, USA.
Kara Wools-KaloustianDepartment of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
Didier K EkoueviUniversité de Bordeaux, ISPED, centre Inserm U897 Épidémiologie-Biostatistique, 33000, Bordeaux, France; Programme PAC-CI, Site ANRS de Côte d'Ivoire, Abidjan, Côte d'Ivoire; Université de Lomé, Faculté des Sciences de la Santé, Départment de Santé Publique, Lomé, Togo.
Matthias EggerInstitute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland.
Jennifer Hemingway-FodayResearch Triangle Institute, Raleigh, NC, USA.
David A CooperKirby Institute, University of New South Wales, Sydney, Australia.
Richard D MooreDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health Baltimore, MD, USA.
Catherine C McGowanDepartment of Medicine, Division of Infectious Diseases, Vanderbilt School of Medicine, Nashville, TN, USA.
Denis NashEpidemiology and Biostatistics Program, Hunter College, City University of New York, New York, NY, USA; Doctor of Public Health Programs (CUNY SPH), School of Public Health, City University of New York, New York, NY, USA.
International Epidemiologic Databases to Evaluate AIDS (IeDEA) Collaboration

Funding

University of Washington/Fred Hutch Center for AIDS ResearchP30AI027757 · NIAID · UNIVERSITY OF WASHINGTON · PI EDWIN ROBERTO ORELLANA · 1988 to 2026
$104.9M
Unsolicited R24 for the CFAR-Network of Integrated Clinical Sciences, CNICSR24AI067039 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Michael S. Saag · 2006 to 2026
$99.4M
Virology CoreP30AI027767 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Latesha Ellen Elopre · 1988 to 2026
$84.1M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
North American AIDS Cohorts on Collaboration and Design (NAACCORD)U01AI069918 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Keri Nicole Althoff, RICHARD Douglas MOORE · 2006 to 2026
$65.2M
East Africa International Epidemiology Database to evaluate AIDS (IeDEA) Regional ConsortiumU01AI069911 · NIAID · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI AGGREY SEMWENDERO SEMEERE, Kara Kay Wools-Kaloustian · 2006 to 2026
$57.7M
Observational Antiretroviral Studies In Southern Africa (OASIS) CollaborationU01AI069924 · NIAID · UNIVERSITAT BERN · PI Cleophas Chimbetete, Mary-Ann Davies · 2006 to 2026
$55.9M
WG3: HIV, Co-infections and Co-morbiditiesP30AI036219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI Alan David Levine · 1994 to 2026
$50.0M
The Statistics, Data Science, and Data Management (SDM) CoreP30MH043520 · NIMH · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI Claude Ann Mellins · 2003 to 2026
$48.2M
The Asia-Pacific HIV Research CollaborationU01AI069907 · NIAID · FOUNDATION FOR AIDS RESEARCH · PI ANNETTE H SOHN · 2006 to 2026
$44.8M
CCASAnet: Caribbean, Central and South America NetworkU01AI069923 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Pedro Enrique Cahn, Jessica L Castilho · 2006 to 2026
$41.6M
NCATS NIH HHS KL2 TR000421NCATS NIH HHS UL1 TR000083NCATS NIH HHS UL1-TR000083NCATS NIH HHS UL1 TR000445NCI NIH HHS N02 CP055504NIAAA NIH HHS R01 AA016893NIAAA NIH HHS R01-AA16893NIAID NIH HHS K24 AI065298NIAID NIH HHS K24-AI065298NIAID NIH HHS P30 AI027757NIAID NIH HHS P30 AI027767NIAID NIH HHS P30 AI036219NIAID NIH HHS P30-AI036219NIAID NIH HHS P30 AI050410NIAID NIH HHS P30 AI054999NIAID NIH HHS P30 AI094189NIAID NIH HHS P30-AI094189NIAID NIH HHS P30-AI27757NIAID NIH HHS P30-AI27767NIAID NIH HHS P30-AI50410NIAID NIH HHS P30-AI54999NIAID NIH HHS R24 AI067039NIAID NIH HHS R24-AI067039NIAID NIH HHS U01 AI069907NIAID NIH HHS U01AI069907NIAID NIH HHS U01 AI069911NIAID NIH HHS U01AI069911NIAID NIH HHS U01 AI069918NIAID NIH HHS U01AI069918NIAID NIH HHS U01 AI069919NIAID NIH HHS U01AI069919NIAID NIH HHS U01 AI069923NIAID NIH HHS U01AI069923NIAID NIH HHS U01 AI069924NIAID NIH HHS U01AI069924NIAID NIH HHS U01 AI096186NIDA NIH HHS K24 DA000432NIDA NIH HHS K24-DA00432NIDA NIH HHS R01-DA11602NIDA NIH HHS U01 DA036935NIDA NIH HHS U01-DA036935NIMH NIH HHS P30 MH043520PHS HHS U01A096299PHS HHS U01A1096186
6 · The paper itself

Abstract

introductionHIV care and treatment programmes worldwide are transforming as they push to deliver universal access to essential prevention, care and treatment services to persons living with HIV and their communities. The characteristics and capacity of these HIV programmes affect patient outcomes and quality of care. Despite the importance of ensuring optimal outcomes, few studies have addressed the capacity of HIV programmes to deliver comprehensive care. We sought to describe such capacity in HIV programmes in seven regions worldwide.

methodsStaff from 128 sites in 41 countries participating in the International epidemiologic Databases to Evaluate AIDS completed a site survey from 2009 to 2010, including sites in the Asia-Pacific region (n=20), Latin America and the Caribbean (n=7), North America (n=7), Central Africa (n=12), East Africa (n=51), Southern Africa (n=16) and West Africa (n=15). We computed a measure of the comprehensiveness of care based on seven World Health Organization-recommended essential HIV services.

resultsMost sites reported serving urban (61%; region range (rr): 33-100%) and both adult and paediatric populations (77%; rr: 29-96%). Only 45% of HIV clinics that reported treating children had paediatricians on staff. As for the seven essential services, survey respondents reported that CD4+ cell count testing was available to all but one site, while tuberculosis (TB) screening and community outreach services were available in 80 and 72%, respectively. The remaining four essential services - nutritional support (82%), combination antiretroviral therapy adherence support (88%), prevention of mother-to-child transmission (PMTCT) (94%) and other prevention and clinical management services (97%) - were uniformly available. Approximately half (46%) of sites reported offering all seven services. Newer sites and sites in settings with low rankings on the UN Human Development Index (HDI), especially those in the President's Emergency Plan for AIDS Relief focus countries, tended to offer a more comprehensive array of essential services. HIV care programme characteristics and comprehensiveness varied according to the number of years the site had been in operation and the HDI of the site setting, with more recently established clinics in low-HDI settings reporting a more comprehensive array of available services. Survey respondents frequently identified contact tracing of patients, patient outreach, nutritional counselling, onsite viral load testing, universal TB screening and the provision of isoniazid preventive therapy as unavailable services.

conclusionsThis study serves as a baseline for on-going monitoring of the evolution of care delivery over time and lays the groundwork for evaluating HIV treatment outcomes in relation to site capacity for comprehensive care.

Indexed as

Comprehensive Health CareHealth Services ResearchAdultAfrica South of the SaharaAmericasAustralasiaChildChild, PreschoolFemaleHIV InfectionsHumansMaleclinic characteristicscomprehensive careHIV/AIDSHIV care capacityresource-limited settings

Identifiers

PMID25516092
PMCPMC4268491

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.